2019
DOI: 10.7759/cureus.4621
|View full text |Cite
|
Sign up to set email alerts
|

Obstructing Duodenal Diffuse Large B-cell Lymphoma with Peritoneal Lymphomatosis with Exceptional Response to R-CHOP

Abstract: Primary small bowel tumors are uncommon and usually carry a poor prognosis. Adenocarcinoma is the predominant histological type while lymphoma is far less common. Small bowel diffuse large B-cell lymphoma (DLBCL) can mimic adenocarcinoma; thus, the distinction can be challenging before tissue examination is performed. Bowel obstruction, as well as peritoneal involvement, are often seen in gastrointestinal (GI) adenocarcinoma cases; however, these features are extremely uncommon with GI lymphomas. Herein, the a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 15 publications
0
3
0
1
Order By: Relevance
“…PL can be seen in many subtypes of non-Hodgkin lymphoma, which seems to converge with DLBCL in most cases (6). Cases of DLBCL with PL presentation that have been recently reported in the literature with a detailed description of clinical course are summarized in Table (8)(9)(10)(11)(12)(13)(14). The patients were middle-aged and older, with no marked difference in proportions between the sexes.…”
Section: Discussionmentioning
confidence: 99%
“…PL can be seen in many subtypes of non-Hodgkin lymphoma, which seems to converge with DLBCL in most cases (6). Cases of DLBCL with PL presentation that have been recently reported in the literature with a detailed description of clinical course are summarized in Table (8)(9)(10)(11)(12)(13)(14). The patients were middle-aged and older, with no marked difference in proportions between the sexes.…”
Section: Discussionmentioning
confidence: 99%
“…The most commonly used chemotherapy regimen is R-CHOP, which is a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. [9,10,14] In patients with unfavorable prognostic factors, DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) may also be a beneficial treatment option [10,15]. Response to treatment is measured using data collected from the post-treatment history, physical, and imaging (PET/CT) scan results.…”
Section: Discussionmentioning
confidence: 99%
“…Para el estudio de la obstrucción intestinal, la tomografía computarizada de abdomen con contraste intravenoso tiene una sensibilidad de 94 a 100 % y una especificidad de 90 a 95 % 18,26 . Es posible encontrar engrosamiento de la pared, lesiones infiltrativas o polipoides, dilatación aneurismática y conglomerados de ganglios linfáticos que disminuyen la luz intestinal 27 .…”
Section: Obstrucción Intestinal E Intususcepciónunclassified